Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection.
|
30614547 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα.
|
30723923 |
2019 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR.
|
31446638 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, 74 patients with chronic HBV infection who had virological responses to 180 μg/week Peg-IFNα-2a treatment were included; 38 (20 and 18 HBeAg positive and negative, respectively) of these patients were treated with 245 mg/day TDF, and 36 (20 and 16 HBeAg positive and negative, respectively) were treated with 0.5 mg/day ETV upon relapse after initial treatment discontinuation.
|
30963812 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Type I IFN (IFN-I) therapy is an important therapeutic option for HBV patients.
|
30150992 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications.
|
30537741 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients.
|
30133478 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-α in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-α against HBV.(Hepatology 2018;67:1237-1252).
|
29059468 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment.
|
29791282 |
2018 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification.
|
29079518 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL).
|
28635613 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM.
|
29901821 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among children with hepatitis B envelope antigen-positive genotype C chronic HBV infection, we compared the efficacy of combination therapy with nucleotide analogues and IFN-α in 11 children with 12 historical cases treated with IFN monotherapy.
|
29981262 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800-1000 mg/d RBV according to weight orally for 48 weeks.
|
29654010 |
2018 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
|
29456079 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A one-year course of Peg-IFN has the advantage of providing immune-mediated control of the hepatitis B virus (HBV) infection, the possibility of achieving a sustained off-treatment response in nearly 30% of the patients and ultimately, HBsAg loss in approximately 30%-50% of the latter patients during long-term off treatment follow-up.
|
29427498 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
|
28236535 |
2017 |
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Vitamin D serum levels and receptor genetic polymorphisms are associated with hepatitis B virus and HIV infections and IFN-λ levels.
|
29493287 |
2017 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
|
28983111 |
2017 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting IFNα to the liver may be a strategy to increase its efficacy locally and may increase efficacy of IFNα-based therapy of HBV infection.
|
28709686 |
2017 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities.
|
28450868 |
2017 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher IFN-<i>λ</i>3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and HCV resolution.
|
29226133 |
2017 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of FN expression significantly inhibited HBV DNA replication and protein synthesis through activating endogenous IFN-α production.
|
27023403 |
2016 |